Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology | Nephrology/Urology
Renal Cell Carcinoma
CTSU/ECOG E2805: A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Resected Renal Cell Carcinoma
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
The BeST Trial: A Randomized Phase II Study of VEGF, RAF kinase, and mTOR
Study VEG108844, a Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
The purpose of this study are to determine the safety profile of MDX-1411; determine the maximum tolerated dose (MTD); and determine the dose-limiting toxicity (DLT) of MDX-1411 when administered every 14 days to subjects with advanced or recurrent clear cell renal cell carcinoma (ccRCC)
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
A clinical trial evaluate the safety and efficacy of a study drug versus placebo in patients with a clear cell renal cell carcinoma and a high risk of recurrence
Study for high risk recurrence of renal cell carcinoma after surgical treatment
A clinical trial evaluate the safety and efficacy of a study drug versus placebo in patients with a clear cell renal cell carcinoma and a high risk of recurrence
A Multi-Center, Randomized Phase III Study of Adjuvant Oncophage? Versus Observation in Subjects With High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma.
The purpose of this study are to determine the safety profile of MDX-1411; determine the maximum tolerated dose (MTD); and determine the dose-limiting toxicity (DLT) of MDX-1411 when administered every 14 days to subjects with advanced or recurrent clear cell renal cell carcinoma (ccRCC)
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
The purpose of this study are to determine the safety profile of MDX-1411; determine the maximum tolerated dose (MTD); and determine the dose-limiting toxicity (DLT) of MDX-1411 when administered every 14 days to subjects with advanced or recurrent clear cell renal cell carcinoma (ccRCC)
The purpose of this study are to determine the safety profile of MDX-1411; determine the maximum tolerated dose (MTD); and determine the dose-limiting toxicity (DLT) of MDX-1411 when administered every 14 days to subjects with advanced or recurrent clear cell renal cell carcinoma (ccRCC)
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
Children with Chronic Renal Insufficiency and taking Growth Hormone are needed for a research study
Men and Women ages 18 and over with untreated advanced renal cell carcinoma needed for a research study.
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
